Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Roivant Sciences

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers

A Relative Strength Rating upgrade for Roivant stock shows improving technical performance. Will it continue?

Investors Business Daily

The 'Extremely Positive' Results That Helped Roivant Leapfrog Its 50-Day Line, Nearing A Breakout

Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.

Investors Business Daily

Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its prospects.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Roivant higher as Vivek Ramaswamy-found firm sells bowel disease drug for $7.1 billion

Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.

The Street

Vivek Ramaswamy: the ‘millennial tech bro’ running for president

The multimillionaire former biotech executive Vivek Ramaswamy took centre stage at the first Republican debate last week as he bids to win his party’s 2024 presidential nomination.

The Week

Who is Vivek Ramaswamy? Trump nominates Ramaswamy and Elon Musk to lead new efficiency department

Vivek Ramaswamy is the son of an immigrant family from Kerala

Evening Standard

11 Revived Stocks That Traded For $5 Or Less Are Now Worth Billions

Investors are even willing to dip into the cheap-stock territory outside the S&P 500 — and it's paying off handsomely so far.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Roivant Sciences

Within the last quarter, Roivant Sciences (NASDAQ:ROIV) has observed the following analyst ratings:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.